Media Availability: Study Finds PrEP Use Feasible Among High-Risk Groups in U.S. Community Settings

Media Availability: Study Finds PrEP Use Feasible Among High-Risk Groups in U.S. Community Settings

Monday July 20, 2015

NIAID Study Finds PrEP Use Feasible among High-Risk Groups in U.S. Community Settings

A majority of men who have sex with men and transgender women at high risk for HIV infection took anti-HIV medication for pre-exposure prophylaxis (PrEP) most of the time in a multi-site U.S. study examining use of this HIV prevention strategy outside of a clinical trial. Findings from the NIAID-funded study, called the PrEP Demo Project, will be presented tomorrow at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention in Vancouver, Canada.